Preoperative SRS Improves Outcomes in Patients With Metastatic Brain Tumors

By News Release


In a new study from Wake Forest University School of Medicine and Atrium Health Levine Cancer Institute, researchers highlight improved outcomes for patients treated with preoperative stereotactic radiosurgery (SRS), particularly in rates of tumor recurrence, adverse radiation effects and spread of tumor cells to the fluid outside of the brain, which is called meningeal disease. The study findings appear online in JAMA Oncology.

“Postoperative SRS is currently the standard of care in these patients, but there is a growing body of research that shows preoperative SRS has advantages,” said Roshan Prabhu, MD, a radiation oncologist at Atrium Health Levine Cancer Institute, in Charlotte, North Carolina, and an adjunct associate professor of radiation oncology at Wake Forest University School of Medicine.

According to Prabhu, who is the lead corresponding author of the study, there are multiple reasons why preoperative SRS may be better than postoperative SRS. In preoperative SRS, the tumor is intact, so providers can more precisely see the area that needs treatment.

“We’ve also conducted research that shows there’s a higher risk of tumor cells spreading to the fluid around the brain when surgery occurs first,” Prabhu said. “Preoperative SRS can help minimize that risk.”

In the study, researchers compiled data from a multicenter and international cohort of 404 patients who underwent preoperative SRS and surgical resection of brain metastases.

To analyze preoperative SRS outcomes, researchers looked at cavity local recurrence, adverse radiation effects and meningeal disease, which occurs when the cancer spreads to nearby fluid and can grow on the surface of the brain. Adverse radiation effects include swelling, inflammation and radiation necrosis, a condition in which there isn’t enough blood supply to tissues and can result in long-term swelling.

The two-year cavity local recurrence rate was 13.7%. The two-year meningeal disease rate was 5.8%, and the two-year symptomatic adverse radiation effect rate was 5%.

While this study did not directly compare outcomes with patients treated with postoperative SRS, recent studies show postoperative SRS cavity recurrence rates to be 22% to 39%, meningeal disease rates to be 16% to 21%, and adverse radiation effects rates to be 7% to 18%.

Additionally, novel risk factors for these outcomes after treatment with preoperative SRS were described, such as extent of resection, tumor type, number of preoperative SRS fractions used and type of surgery.

“We found negative outcomes to be notably low with preoperative SRS, especially when compared to what is expected after postoperative SRS,” Prabhu said. “By simply changing the sequencing of treatment, it can potentially improve outcomes and increase survival.”

These data served as the basis for a national phase 3 randomized clinical trial comparing preoperative SRS to postoperative SRS, which is currently enrolling patients at multiple sites including Atrium Health Levine Cancer Institute.